Amphastar Pharmaceuticals (AMPH) EBIT (2016 - 2025)
Historic EBIT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $25.3 million.
- Amphastar Pharmaceuticals' EBIT fell 5561.63% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 3001.75%. This contributed to the annual value of $205.4 million for FY2024, which is 428.05% up from last year.
- Per Amphastar Pharmaceuticals' latest filing, its EBIT stood at $25.3 million for Q3 2025, which was down 5561.63% from $42.2 million recorded in Q2 2025.
- Over the past 5 years, Amphastar Pharmaceuticals' EBIT peaked at $72.7 million during Q3 2023, and registered a low of $10.3 million during Q1 2021.
- Over the past 5 years, Amphastar Pharmaceuticals' median EBIT value was $36.9 million (recorded in 2023), while the average stood at $36.0 million.
- Per our database at Business Quant, Amphastar Pharmaceuticals' EBIT skyrocketed by 74237.58% in 2021 and then crashed by 5561.63% in 2025.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' EBIT stood at $24.3 million in 2021, then soared by 56.0% to $37.8 million in 2022, then skyrocketed by 42.68% to $54.0 million in 2023, then fell by 16.37% to $45.1 million in 2024, then tumbled by 43.91% to $25.3 million in 2025.
- Its EBIT stands at $25.3 million for Q3 2025, versus $42.2 million for Q2 2025 and $37.3 million for Q1 2025.